Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma

Cui,Shiyun; Fan,Lei; Sun,Xinnan; Cai,Yucheng; Wang,Ting; Li,Ping; Wang,Rong; Liu,Lianke

doi:10.3892/ol.2025.14990

Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma

Authors:
- Shiyun Cui
- Lei Fan
- Xinnan Sun
- Yucheng Cai
- Ting Wang
- Ping Li
- Rong Wang
- Lianke Liu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of General Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China, Department of Clinical Medicine, The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China
Published online on: March 24, 2025 https://doi.org/10.3892/ol.2025.14990
Article Number: 244
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer is a type of digestive system tumor with a high degree of malignancy. In recent years, research has been conducted on immunotherapy, chemotherapy and radiation therapy for esophageal cancer. However, there are still shortcomings in the improvement of 5‑year survival rates. In order to explore more therapy options, the present study evaluated the efficacy and safety of recombinant human‑endostatin (rh‑endostatin) combined with sintilimab and chemotherapy for the first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). This retrospective study included data from 31 patients with unresectable locally advanced or metastatic esophageal cancer treated between January 2019 and December 2023, and was approved by the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). All patients received first‑line treatment combining rh‑endostatin with sintilimab, paclitaxel liposome and platinum. Following the completion of 6 cycles, maintenance therapy with sintilimab was administered until disease progression occurred. The objective response rate (ORR), disease control rate (DCR), progression‑free survival (PFS) time, overall survival (OS) time and adverse events (AEs) were observed. Symptomatic or supportive care was administered as needed, according to the clinical discretion of the treating physician. As of July 17, 2024, the median follow‑up time was 13.07 months, with a median PFS time of 8.30 months (95% confidence interval, 3.442‑13.158 months). For these 31 patients, the ORR was 67.7% (21/31), while the DCR was 93.5% (29/31). The median OS time reached 23.07 months. Furthermore, 77.4% of patients experienced at least one treatment‑related AE (TRAE), and grade 3 TRAEs occurred in 8 patients (25.8%). No unexpected AEs were observed. In conclusion, rh‑endostatin combined with sintilimab and chemotherapy exhibited positive efficacy and safety in patients with advanced ESCC, providing a promising treatment regimen for these patients.

View Figures

View References

1	GBD 2017 Oesophageal Cancer Collaborators, . The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5:582–597. 2020. View Article : Google Scholar : PubMed/NCBI
2	Medical Affairs Bureau of the National Health and Health Commission of the People's Republic of China, . Esophageal cancer diagnosis and treatment guidelines (2022 edition). Zhonghua Wei Chang Wai Ke Za Zhi. 21:1247–1268. 2022.(In Chinese).
3	Sasaki Y and Kato K: Chemoradiotherapy for esophageal squamous cell cancer. Jpn J Clin Oncol. 46:805–810. 2016. View Article : Google Scholar : PubMed/NCBI
4	Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A and Imamura Y: Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 50:12–20. 2020. View Article : Google Scholar : PubMed/NCBI
5	Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al: Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet. 398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
6	Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al: Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 386:449–462. 2022. View Article : Google Scholar : PubMed/NCBI
7	Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, et al: First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind phase 3 trial. Nat Med. 29:473–482. 2023. View Article : Google Scholar : PubMed/NCBI
8	Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, et al: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 24:483–495. 2023. View Article : Google Scholar : PubMed/NCBI
9	Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, et al: Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st Randomized clinical trial. JAMA. 326:916–925. 2021. View Article : Google Scholar : PubMed/NCBI
10	Hoy SM: Sintilimab: First global approval. Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
11	Lu Y, Liao L, Du K, Mo J, Zou X, Liang J, Chen J, Tang W, Su L, Wu J, et al: Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma. BMC Cancer. 24:1332024. View Article : Google Scholar : PubMed/NCBI
12	Li F, Zhang DB, Ma Y, Song Y and Duan XL: Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis. Pak J Med Sci. 40:648–651. 2024. View Article : Google Scholar : PubMed/NCBI
13	Zhou SQ, Wan P, Zhang S, Ren Y, Li HT and Ke QH: Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol. 15:859–866. 2024. View Article : Google Scholar : PubMed/NCBI
14	Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial. BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI
15	Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S and Carbone DP: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 101:4878–4886. 2003. View Article : Google Scholar : PubMed/NCBI
16	Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S, Luo F and He J: The research Progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol. 13:8028462022. View Article : Google Scholar : PubMed/NCBI
17	Sun Y, Wang JW, Liu YY, Yu QT, Zhang YP, Li K, Xu LY, Luo SX, Qin FZ, Chen ZT, et al: Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rhendostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac Cancer. 4:440–448. 2013. View Article : Google Scholar : PubMed/NCBI
18	Pu X, Wang Q, Liu L, Chen B, Li K, Zhou Y, Sheng Z, Liu P, Tang Y, Xu L, et al: Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study. Cancer Med. 12:7724–7733. 2023. View Article : Google Scholar : PubMed/NCBI
19	Huang H, Zhong P, Zhu X, Fu S, Li S, Peng S, Liu Y, Lu Z and Chen L: Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. Front Oncol. 13:11372242023. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Yao Q, Huang M, Wang B, Zhang J, Wang T, Ming Y, Zhou X, Jia Q, Huan Y, et al: A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01). Int J Cancer. 142:2130–2138. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Jin F, Jiang S, Cao J, Meng Y, Xu Y, ChunmengWan g, Chen Y, Yang H, Kong Y, et al: Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. Invest New Drugs. 40:453–460. 2022. View Article : Google Scholar : PubMed/NCBI
22	Tsuchida Y and Therasse P: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol. 37:1–3. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chinese Anti-Cancer Association, . Chinese expert consensus on PD-L1 immunohistochemical detection criteria for non-small cell lung cancer. Chin J Lung Cancer. 23:733–740. 2020.
24	Mischel AM and Rosielle DA: Eastern Cooperative Oncology Group Performance Status #434. J Palliat Med. 25:508–510. 2022. View Article : Google Scholar : PubMed/NCBI
25	National Cancer Institute, . Common Terminology Criteria for Adverse Events v3.0 (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfFebruary 6–2024
26	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
27	Bureau of Medical Administration and National Health Commission of the People's Republic of China, . Standardization for diagnosis and treatment of esophageal cancer (2022 edition). Chin J Dig Surg. 21:1247–1268. 2022.(In Chinese).
28	Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, Meng L, Xin Y and Jiang X: Targeting hypoxia in the tumor microenvironment: A potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 40:242021. View Article : Google Scholar : PubMed/NCBI
29	Khan KA and Kerbel RS: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 15:310–324. 2018. View Article : Google Scholar : PubMed/NCBI
30	Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI
31	Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
32	Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, et al: Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 544:250–254. 2017. View Article : Google Scholar : PubMed/NCBI
33	Schmidt EV: Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin Immunopathol. 41:21–30. 2019. View Article : Google Scholar : PubMed/NCBI
34	Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al: VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors. J Exp Med. 212:139–148. 2015. View Article : Google Scholar : PubMed/NCBI
35	Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP and Bergers G: Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 9:eaak96792017. View Article : Google Scholar : PubMed/NCBI
36	Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM and Emens LA: A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 13:3951–3959. 2007. View Article : Google Scholar : PubMed/NCBI
37	Fuming Qiu, Fan J, Shao M, Yao J, Zhao L, Zhu L, Li B, Fu Y, Li L, Yang Y, et al: Efficacy of two - and three-cycle neoadjuvant sinadilizumab plus platinum-based double-agent chemotherapy in patients with resectable non-small cell lung cancer (neoSCORE): A randomized, single-center, two-arm Phase II trial. J Clin Oncol. 40:8500. 2022. View Article : Google Scholar
38	Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM and Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 11:2127–2135. 1993. View Article : Google Scholar : PubMed/NCBI